vs
安进（AMGN）与万豪国际（MAR）财务数据对比。点击上方公司名可切换其他公司
安进的季度营收约是万豪国际的1.5倍（$9.9B vs $6.7B），安进净利率更高（13.5% vs 6.7%，领先6.9%），安进同比增速更快（8.6% vs 4.1%），过去两年安进的营收复合增速更高（15.1% vs 5.8%）
安进是总部位于美国加利福尼亚州千橡市的跨国生物制药企业，公司名称取自最初的全称「应用分子遗传学」的缩写组合，按营收规模排名位列全球生物医药企业第18位，专注于研发、生产及商业化创新生物药物，为全球患者提供优质治疗选择。
万豪国际是美国跨国酒店管理集团，主营业务为运营、特许经营及授权各类住宿品牌，覆盖酒店、住宅、分时度假等多元物业类型。集团旗下拥有37个以上酒店及时度假品牌，全球布局9000余处经营点位，客房总量超159万间，总部位于美国马里兰州贝塞斯达，脱胎于原万豪集团的酒店业务板块。
AMGN vs MAR — 直观对比
营收规模更大
AMGN
是对方的1.5倍
$6.7B
营收增速更快
AMGN
高出4.5%
4.1%
净利率更高
AMGN
高出6.9%
6.7%
两年增速更快
AMGN
近两年复合增速
5.8%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $9.9B | $6.7B |
| 净利润 | $1.3B | $445.0M |
| 毛利率 | 69.8% | — |
| 营业利润率 | 27.6% | 11.6% |
| 净利率 | 13.5% | 6.7% |
| 营收同比 | 8.6% | 4.1% |
| 净利润同比 | 112.6% | -2.2% |
| 每股收益（稀释后） | $2.45 | $1.67 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AMGNMAR
| Q4 25 | $9.9B | $6.7B | ||
| Q3 25 | $9.6B | $6.5B | ||
| Q2 25 | $9.2B | $6.7B | ||
| Q1 25 | $8.1B | $6.3B | ||
| Q4 24 | $9.1B | $6.4B | ||
| Q3 24 | $8.5B | $6.3B | ||
| Q2 24 | $8.4B | $6.4B | ||
| Q1 24 | $7.4B | $6.0B |
净利润AMGNMAR
| Q4 25 | $1.3B | $445.0M | ||
| Q3 25 | $3.2B | $728.0M | ||
| Q2 25 | $1.4B | $763.0M | ||
| Q1 25 | $1.7B | $665.0M | ||
| Q4 24 | $627.0M | $455.0M | ||
| Q3 24 | $2.8B | $584.0M | ||
| Q2 24 | $746.0M | $772.0M | ||
| Q1 24 | $-113.0M | $564.0M |
毛利率AMGNMAR
| Q4 25 | 69.8% | — | ||
| Q3 25 | 67.8% | — | ||
| Q2 25 | 67.2% | — | ||
| Q1 25 | 63.6% | — | ||
| Q4 24 | 65.7% | — | ||
| Q3 24 | 61.1% | — | ||
| Q2 24 | 61.4% | — | ||
| Q1 24 | 57.0% | — |
营业利润率AMGNMAR
| Q4 25 | 27.6% | 11.6% | ||
| Q3 25 | 26.4% | 18.2% | ||
| Q2 25 | 28.9% | 18.3% | ||
| Q1 25 | 14.5% | 15.1% | ||
| Q4 24 | 25.4% | 11.7% | ||
| Q3 24 | 24.1% | 15.1% | ||
| Q2 24 | 22.8% | 18.6% | ||
| Q1 24 | 13.3% | 14.7% |
净利率AMGNMAR
| Q4 25 | 13.5% | 6.7% | ||
| Q3 25 | 33.7% | 11.2% | ||
| Q2 25 | 15.6% | 11.3% | ||
| Q1 25 | 21.2% | 10.6% | ||
| Q4 24 | 6.9% | 7.1% | ||
| Q3 24 | 33.3% | 9.3% | ||
| Q2 24 | 8.9% | 12.0% | ||
| Q1 24 | -1.5% | 9.4% |
每股收益（稀释后）AMGNMAR
| Q4 25 | $2.45 | $1.67 | ||
| Q3 25 | $5.93 | $2.67 | ||
| Q2 25 | $2.65 | $2.78 | ||
| Q1 25 | $3.20 | $2.39 | ||
| Q4 24 | $1.17 | $1.64 | ||
| Q3 24 | $5.22 | $2.07 | ||
| Q2 24 | $1.38 | $2.69 | ||
| Q1 24 | $-0.21 | $1.93 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $9.1B | $358.0M |
| 总债务越低越好 | $54.6B | $15.0B |
| 股东权益账面价值 | $8.7B | $-3.8B |
| 总资产 | $90.6B | $27.5B |
| 负债/权益比越低杠杆越低 | 6.31× | — |
8季度趋势，按日历期对齐
现金及短期投资AMGNMAR
| Q4 25 | $9.1B | $358.0M | ||
| Q3 25 | $9.4B | $678.0M | ||
| Q2 25 | $8.0B | $671.0M | ||
| Q1 25 | $8.8B | $523.0M | ||
| Q4 24 | $12.0B | $396.0M | ||
| Q3 24 | $9.0B | $394.0M | ||
| Q2 24 | $9.3B | $349.0M | ||
| Q1 24 | $9.7B | $429.0M |
总债务AMGNMAR
| Q4 25 | $54.6B | $15.0B | ||
| Q3 25 | $54.6B | $14.4B | ||
| Q2 25 | $56.2B | $14.5B | ||
| Q1 25 | $57.4B | $14.1B | ||
| Q4 24 | $60.1B | $13.1B | ||
| Q3 24 | $60.4B | $12.7B | ||
| Q2 24 | $62.6B | $12.2B | ||
| Q1 24 | $64.0B | $11.7B |
股东权益AMGNMAR
| Q4 25 | $8.7B | $-3.8B | ||
| Q3 25 | $9.6B | $-3.1B | ||
| Q2 25 | $7.4B | $-3.0B | ||
| Q1 25 | $6.2B | $-3.2B | ||
| Q4 24 | $5.9B | $-3.0B | ||
| Q3 24 | $7.5B | $-2.4B | ||
| Q2 24 | $5.9B | $-2.1B | ||
| Q1 24 | $5.0B | $-1.6B |
总资产AMGNMAR
| Q4 25 | $90.6B | $27.5B | ||
| Q3 25 | $90.1B | $27.8B | ||
| Q2 25 | $87.9B | $27.3B | ||
| Q1 25 | $89.4B | $26.7B | ||
| Q4 24 | $91.8B | $26.2B | ||
| Q3 24 | $90.9B | $26.2B | ||
| Q2 24 | $90.9B | $25.7B | ||
| Q1 24 | $93.0B | $25.8B |
负债/权益比AMGNMAR
| Q4 25 | 6.31× | — | ||
| Q3 25 | 5.67× | — | ||
| Q2 25 | 7.57× | — | ||
| Q1 25 | 9.24× | — | ||
| Q4 24 | 10.23× | — | ||
| Q3 24 | 8.02× | — | ||
| Q2 24 | 10.57× | — | ||
| Q1 24 | 12.75× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $1.6B | $829.0M |
| 自由现金流经营现金流 - 资本支出 | $961.0M | — |
| 自由现金流率自由现金流/营收 | 9.7% | — |
| 资本支出强度资本支出/营收 | 6.5% | — |
| 现金转化率经营现金流/净利润 | 1.20× | 1.86× |
| 过去12个月自由现金流最近4个季度 | $8.1B | — |
8季度趋势，按日历期对齐
经营现金流AMGNMAR
| Q4 25 | $1.6B | $829.0M | ||
| Q3 25 | $4.7B | $1.1B | ||
| Q2 25 | $2.3B | $643.0M | ||
| Q1 25 | $1.4B | $647.0M | ||
| Q4 24 | $4.8B | $318.0M | ||
| Q3 24 | $3.6B | $880.0M | ||
| Q2 24 | $2.5B | $772.0M | ||
| Q1 24 | $689.0M | $779.0M |
自由现金流AMGNMAR
| Q4 25 | $961.0M | — | ||
| Q3 25 | $4.2B | $951.0M | ||
| Q2 25 | $1.9B | $488.0M | ||
| Q1 25 | $980.0M | $512.0M | ||
| Q4 24 | $4.4B | $-24.0M | ||
| Q3 24 | $3.3B | $706.0M | ||
| Q2 24 | $2.2B | $647.0M | ||
| Q1 24 | $459.0M | $670.0M |
自由现金流率AMGNMAR
| Q4 25 | 9.7% | — | ||
| Q3 25 | 44.4% | 14.7% | ||
| Q2 25 | 20.8% | 7.2% | ||
| Q1 25 | 12.0% | 8.2% | ||
| Q4 24 | 48.4% | -0.4% | ||
| Q3 24 | 39.0% | 11.3% | ||
| Q2 24 | 26.5% | 10.0% | ||
| Q1 24 | 6.2% | 11.2% |
资本支出强度AMGNMAR
| Q4 25 | 6.5% | — | ||
| Q3 25 | 4.6% | 2.2% | ||
| Q2 25 | 4.0% | 2.3% | ||
| Q1 25 | 5.0% | 2.2% | ||
| Q4 24 | 4.1% | 5.3% | ||
| Q3 24 | 3.0% | 2.8% | ||
| Q2 24 | 2.8% | 1.9% | ||
| Q1 24 | 3.1% | 1.8% |
现金转化率AMGNMAR
| Q4 25 | 1.20× | 1.86× | ||
| Q3 25 | 1.46× | 1.50× | ||
| Q2 25 | 1.59× | 0.84× | ||
| Q1 25 | 0.80× | 0.97× | ||
| Q4 24 | 7.61× | 0.70× | ||
| Q3 24 | 1.26× | 1.51× | ||
| Q2 24 | 3.30× | 1.00× | ||
| Q1 24 | — | 1.38× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AMGN
| Products | $9.4B | 95% |
| Xgeva | $291.0M | 3% |
| Vectibix | $163.0M | 2% |
| Aranesp | $115.0M | 1% |
MAR
暂无分部数据
